Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro

Neuropharmacology

Volumn 49, Issue 7, 2005, Pages 1088-1099

  Hirohata, Mie ^a,b   Ono, Kenjiro ^a   Naiki, Hironobu ^b,c   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Amyloid fibrils; Alzheimer's disease; Electron microscopy; Non steroidal anti inflammatory drugs; Thioflavin T

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; KETOPROFEN; MECLOFENAMATE SODIUM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC SULFIDE; THIOFLAVINE;

ALZHEIMER DISEASE; ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; ELECTRON MICROSCOPY; FLUORESCENCE SPECTROSCOPY; PH; PRIORITY JOURNAL; TEMPERATURE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOIDOSIS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; MICROSCOPY, ELECTRON; MICROSCOPY, FLUORESCENCE; NEUROFIBRILS;

EID: 27144513779     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2005.07.004     Document Type: Article

References (40)

1. H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, N.R. Cooper, P. Eikelenboom, M. Emmerling, B.L. Fiebich, C.E. Finch, S. Frautschy, W.S. Griffin, H. Hampel, M. Hull, G. Landreth, L. Lue, R. Mrak, I.R. Mackenzie, P.L. McGeer, M.K. O'Banion, J. Pachter, G. Pasinetti, C. Plata-Salaman, J. Rogers, R. Rydel, Y. Shen, W. Streit, R. Strohmeyer, I. Tooyoma, F.L. Van Muiswinkel, R. Veerhuis, D. Walker, S. Webster, B. Wegrzyniak, G. Wenk, and T. Wyss-Coray Inflammation and Alzheimer's disease Neurobiol. Aging 21 2000 383 421
2. B. Bannwarth, F. Lapicque, F. Pehourcq, P. Gillet, T. Schaeverbeke, C. Laborde, J. Dehais, A. Gaucher, and P. Netter Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid Br. J. Clin. Pharmacol 40 1995 266 269
3. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem 72 1976 248 254
4. P. Eikelenboom, C. Bate, W.A. Van Gool, J.J. Hoozemans, J.M. Rozemuller, R. Veerhuis, and A. Williams Neuroinflammation in Alzheimer's disease and prion disease Glia 40 2002 232 239
5. J.L. Eriksen, S.A. Sagi, T.E. Smith, S. Weggen, P. Das, D.C. McLendon, V.V. Ozols, K.W. Jessing, K.H. Zavitz, E.H. Koo, and T.E. Golde NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo J. Clin. Invest 112 2003 440 449
6. G. Forloni, L. Colombo, L. Girola, F. Tagliavini, and M. Salmona Anti-amyloidogenic activity of tetracyclines: studies in vitro FEBS Lett. 487 2001 404 407
7. H.M. Gao, B. Liu, W. Zhang, and J.S. Hong Novel anti-inflammatory therapy for Parkinson's disease Trends Pharmacol. Sci. 24 2003 395 401
8. Y. Gong, L. Chang, K.L. Viola, P.N. Lacor, M.P. Lambert, C.E. Finch, G.A. Krafft, and W.L. Klein Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss Proc. Natl. Acad. Sci. USA 100 2003 10417 10422
9. K. Hasegawa, I. Yamaguchi, S. Omata, F. Gejyo, and H. Naiki Interaction between Aβ(1-42) and Aβ(1-40) in Alzheimer's β-amyloid fibril formation in vitro Biochemistry 38 1999 15514 15521
10. K. Hasegawa, K. Ono, M. Yamada, and H. Naiki Kinetic modeling and determination of reaction constants of Alzheimer's β-amyloid fibril extension and dissociation using surface plasmon resonance Biochemistry 41 2002 13489 13498
11. J.T. Jarrett, and P.T. Lansbury Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73 1993 1055 1058
12. R. Kisilevsky, L.J. Lemieux, P.E. Fraser, X. Kong, P.G. Hultin, and W.A. Szarek Arresting amyloidosis in vivo using small-molecule anionic sulfonates or sulfates: implications for Alzheimer's disease Nat. Med 1 1995 143 148
13. J. Li, M. Zhu, A.B. Manning-Bog, D.A. Di Monte, and A.L. Fink Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease FASEBJ 9 2004 962 964
14. G.P. Lim, F. Yang, T. Chu, P. Chen, W. Beech, B. Teter, T. Tran, O. Ubeda, K.H. Ashe, S.A. Frautschy, and G.M. Cole Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease J. Neurosci 20 2000 5709 5714
15. G.P. Lim, F. Yang, T. Chu, E. Gahtan, O. Ubeda, W. Beech, J.B. Overmier, K. Hsiao-Ashec, S.A. Frautschy, and G.M. Cole Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice Neurobiol. Aging 22 2001 983 991
16. P.L. McGeer, and E.G. McGeer The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases Brain. Res. Brain. Res. Rev. 21 1995 195 218
17. P.L. McGeer, M. Schulzer, and E.G. McGeer Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies Neurology 47 1996 425 432
18. H. Naiki, and F. Gejyo Kinetic analysis of amyloid fibril formation Methods Enzymol 309 1999 305 318
19. H. Naiki, and K. Nakakuki First-order kinetic model of Alzheimer's β-amyloid fibril extension in vitro Lab. Invest 74 1996 374 383
20. H. Naiki, K. Hasegawa, I. Yamaguchi, H. Nakamura, F. Gejyo, and K. Nakakuki Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer's β-amyloid fibril formation in vitro Biochemistry 37 1998 17882 17889
21. K. Ono, K. Hasegawa, M. Yamada, and H. Naiki Nicotine breaks down preformed Alzheimer's β-amyloid fibrils in vitro Biol. Psychiatry 52 2002 880 886
22. K. Ono, K. Hasegawa, Y. Yoshiike, A. Takashima, M. Yamada, and H. Naiki Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's β-amyloid fibrils in vitro J. Neurochem 81 2002 434 440
23. K. Ono, Y. Yoshiike, A. Takashima, K. Hasegawa, H. Naiki, and M. Yamada Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease J. Neurochem 87 2003 172 181
24. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's β-amyloid fibrils in vitro Biochim. Biophys. Acta 1690 2004 193 202
25. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada Curcumin has potent anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro J. Neurosci. Res. 75 2004 742 750
26. M. Pappolla, P. Bozner, C. Soto, H. Shao, N.K. Robakis, M. Zagorski, B. Frangione, and J. Ghiso Inhibition of Alzheimer β-fibrillogenesis by melatonin J. Biol. Chem. 273 1998 7185 7188
27. C.J. Pike, A.J. Walencewicz-Wasserman, J. Kosmoski, D.H. Cribbs, C.G. Glabe, and C.W. Cotman Structure-activity analyses of β-amyloid peptides: contributions of the β25-35 region to aggregation and neurotoxicity J. Neurochem 64 1995 253 265
28. J. Rogers, S. Webster, L.F. Lue, L. Brachova, W.H. Civin, M. Emmerling, B. Shivers, D. Walker, and P. McGeer Inflammation and Alzheimer's disease pathogenesis Neurobiol. Aging 17 1996 681 686
29. S.A. Sagi, S. Weggen, J. Eriksen, T.E. Golde, and E.H. Koo The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of κB kinase, and NF κB, do not reduce amyloid β42 production J. Biol. Chem. 278 2003 31825 31830
30. D.J. Selkoe Alzheimer's disease: genes, proteins, and therapy Physiol. Rev. 81 2001 741 766
31. C. Soto, M.S. Kindy, M. Baumann, and B. Frangione Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation Biochem. Biophys. Res. Commun 226 1996 672 680
32. Y. Takahashi, I. Hayashi, Y. Tominari, K. Rikimaru, Y. Morohashi, T. Kan, H. Natsugari, T. Fukuyama, T. Tomita, and T. Iwatsubo Sulindac sulfide is a noncompetitive γ-secretase inhibitor that preferentially reduces Aβ42 generation J. Biol. Chem. 278 2003 18664 18670
33. T. Thomas, T.G. Nadackal, and K. Thomas Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation NeuroReport 12 2001 3263 3267
34. T. Tomiyama, A. Shoji, K. Kataoka, Y. Suwa, S. Asano, H. Kaneko, and N. Endo Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger J. Biol. Chem. 271 1996 6839 6844
35. B.A. in 't Veld, L.J. Launer, A.W. Hoes, A. Ott, A. Hofman, M.M. Breteler, and B.H. Stricker NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol Aging 19 1998 607 611
36. B.A. in 't Veld, A. Ruitenberg, A. Hofman, L.J. Launer, C.M. van Duijn, T. Stijnen, M.M. Breteler, and B.H. Stricker Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease N. Engl. J. Med 345 2001 1515 1521
37. S. Weggen, J.L. Eriksen, P. Das, S.A. Sagi, R. Wang, C.U. Pietrzik, K.A. Findlay, T.E. Smith, M.P. Murphy, T. Bulter, D.E. Kang, N. Marquez-Sterling, T.E. Golde, and E.H. Koo A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity Nature 414 2001 212 216
38. F. Yang, G.P. Lim, A.N. Begum, O.J. Ubeda, M.R. Simmons, S.S. Ambegaokar, P.P. Chen, R. Kayed, C.G. Glabe, S.A. Frautschy, and G.M. Cole Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo J. Biol. Chem. 280 2005 5892 5901
39. H. Zeng, Y. Zhang, L. Peng, H. Shao, N.K. Menon, J. Yang, A.R. Salomon, R.P. Freidland, and M.G. Zagorski Nicotine and amyloid formation Biol. Psychiatry 49 2001 248 257
40. Y. Zhou, Y. Su, B. Li, F. Liu, J.W. Ryder, X. Wu, P.A. Gonzalez-DeWhitt, V. Gelfanova, J.E. Hale, P.C. May, S.M. Paul, and B. Ni Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Aβ42 by inhibiting Rho Science 302 2003 1215 1217